Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Mounjaro ® ▼ (tirzepatide)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
What excipients does the Mounjaro® (tirzepatide) KwikPen® contain?
The Mounjaro KwikPen contains inactive ingredients that are listed below. It is contraindicated in patients with hypersensitivity to the active substance or any of the excipients.
List of excipients
Excipients |
Quantity (per0.6mL) |
Purpose of Ingredient |
Sodium phosphate dibasic heptahydrate |
0.8 mg |
Buffer |
Sodium chloride |
1.05 mg |
Tonicity agent |
Hydrochloric acid solution |
as needed |
pH adjustment |
Sodium hydroxide solution |
as needed |
pH adjustment |
Water for injection |
as needed to 0.6 mL |
Vehicle |
Phenol |
1.08 mg |
Preservative |
Benzyl alcohol |
5.4 mg |
Preservative |
Glycerol |
4.8 mg |
Tonicity agent |
Excipients with known effect
Each multiple-dose pre-filled pen contains 5.4 mg Benzyl Alcohol [E1519] in each 0.6 ml dose.1
Benzyl alcohol may cause allergic reactions.1
Patients with hepatic or renal impairment should be informed of the potential risk of metabolic acidosis due to accumulation of benzyl alcohol over time.
References
1Mounjaro [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands. (GB)
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 07 December 2023